GRAIL (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc. is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw. When a cancer signal is detected, the test may also provide information intended to help guide diagnostic follow-up. Galleri is not intended to replace recommended cancer screenings, and it has not been approved or cleared by the U.S. Food and Drug Administration.

GRAIL was founded in 2016 with backing from Illumina, a provider of genomic sequencing technologies, and later operated as an independent publicly traded company. The company primarily serves the U.S. market through healthcare providers and other channels, while conducting research and commercial activities related to early cancer detection in additional geographies. GRAIL is led by Chief Executive Officer Bob Ragusa.

Key Stats

• Today's Range: $133.31 to $142.57
• 50-Day Range: $63.40 to $154.08
• 52-Week Range: $41.50 to $166.48
• Volume: 773,590 shs
• Average Volume: 1.62 million shs
• Market Capitalization: $6.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $102.70
• Consensus Rating: Hold

GRAIL Stock Analysis - MarketRank™

GRAIL scored higher than 29% of companies evaluated by MarketBeat, and ranked 763rd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

GRAIL has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.

Downside Risk

GRAIL has a consensus price target of $102.70, representing about 26.9% downside from its current price of $140.58.

Amount of Analyst Coverage

GRAIL has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GRAIL are expected to decrease in the coming year, from ($10.41) to ($10.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GRAIL is -14.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GRAIL is -14.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GRAIL has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

18.27% of the float of GRAIL has been sold short.

Short Interest Ratio / Days to Cover

GRAIL has a short interest ratio ("days to cover") of 4.14.

Change versus previous month

Short interest in GRAIL has recently decreased by 6.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRAIL does not currently pay a dividend.

Dividend Growth

GRAIL does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.52

News Sentiment

GRAIL has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for GRAIL this week, compared to 9 articles on an average week.

Search Interest

15 people have searched for GRAL on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.

MarketBeat Follows

10 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,095,805.00 in company stock.

Percentage Held by Insiders

1.83% of the stock of GRAIL is held by insiders.

Percentage Held by Institutions

GRAIL has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CIK: 1699031
• Web: grail.com
• Phone: (833) 694-2553
• Fax: N/A
• Employees: 910
• Year Founded: 2016

Price Target and Rating

• Average Price Target for GRAIL: $102.70
• High Price Target: $175.00
• Low Price Target: $56.00
• Potential Upside/Downside: -26.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$408.35 million
• Net Margins: -236.95%
• Pretax Margin: -320.38%
• Return on Equity: -15.88%
• Return on Assets: -14.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.95
• Quick Ratio: 10.95

Sales & Book Value

• Annual Sales: $147.17 million
• Price / Sales: 42.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $66.13 per share
• Price / Book: 2.13

Miscellaneous

• Outstanding Shares: 44,670,000
• Free Float: 43,849,000
• Market Cap: $6.28 billion
• Optionable: Optionable
• Beta: 2.83